These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1276 related articles for article (PubMed ID: 35665782)

  • 21. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
    Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
    Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
    Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
    Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
    Cortés J; Hurvitz SA; Im SA; Iwata H; Curigliano G; Kim SB; Chiu JWY; Pedrini JL; Li W; Yonemori K; Bianchini G; Loi S; Borges GS; Wang X; Bachelot T; Nakatani S; Ashfaque S; Liang Z; Egorov A; Hamilton E
    Nat Med; 2024 Aug; 30(8):2208-2215. PubMed ID: 38825627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
    Iwata H; Xu B; Kim SB; Chung WP; Park YH; Kim MH; Tseng LM; Chung CF; Huang CS; Kim JH; Chiu JWY; Yamashita T; Li W; Egorov A; Nishijima S; Nakatani S; Nishiyama Y; Sugihara M; Cortés J; Im SA
    Cancer Sci; 2024 Sep; 115(9):3079-3088. PubMed ID: 38979893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
    Narayan P; Dilawari A; Osgood C; Feng Z; Bloomquist E; Pierce WF; Jafri S; Kalavar S; Kondratovich M; Jha P; Ghosh S; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2023 Apr; 41(11):2108-2116. PubMed ID: 36780610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J;
    N Engl J Med; 2017 Jul; 377(2):122-131. PubMed ID: 28581356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
    Garrido C; Manoogian M; Ghambire D; Lucas S; Karnoub M; Olson MT; Hicks DG; Tozbikian G; Prat A; Ueno NT; Modi S; Feng W; Pugh J; Hsu C; Tsurutani J; Cameron D; Harbeck N; Fang Q; Khambata-Ford S; Liu X; Inge LJ; Vitazka P
    Virchows Arch; 2024 Jun; 484(6):1005-1014. PubMed ID: 37857998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
    Nishikawa T; Hasegawa K; Matsumoto K; Mori M; Hirashima Y; Takehara K; Ariyoshi K; Kato T; Yagishita S; Hamada A; Kawasaki M; Kawashima S; Tomatsuri S; Nagasaka Y; Yoshida H; Machida R; Hirakawa A; Nakamura K; Yonemori K
    J Clin Oncol; 2023 May; 41(15):2789-2799. PubMed ID: 36977309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
    Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
    Vaz Batista M; Pérez-García JM; Cortez P; Garrigós L; Fernández-Abad M; Gion M; Martínez-Bueno A; Saavedra C; Teruel I; Fernandez-Ortega A; Servitja S; Ruiz-Borrego M; de la Haba-Rodríguez J; Martrat G; Pérez-Escuredo J; Alcalá-López D; Sampayo-Cordero M; Braga S; Cortés J; Llombart-Cussac A
    ESMO Open; 2024 Sep; 9(9):103699. PubMed ID: 39255534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.